📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Alkem Labs Receives EU GMP Compliance Certificate for Baddi Manufacturing Facility
Alkem Laboratories has received a Certificate of GMP Compliance from the German Health Authority for its manufacturing plant located in Baddi, India. This certification follows a successful inspection conducted between November 4 and November 10, 2025. The certificate is valid for a period of three years from the date of inspection, ensuring the facility meets European standards for human medicines. This regulatory clearance is crucial for the company's ability to supply pharmaceutical products to the European market.
Key Highlights
Received 'Certificate of GMP Compliance' from the Department of Pharmacy (Human Medicines) – Germany.
The inspection was conducted at the Baddi, India facility from 04th to 10th November 2025.
The compliance certificate is valid for a period of 3 years from the date of inspection.
The approval follows the initial inspection intimation provided by the company on 10th November 2025.
💼 Action for Investors
Investors should view this as a positive development that de-risks the company's European export potential from the Baddi site. No immediate action is required, but this reinforces Alkem's strong regulatory compliance track record.
Alkem Labs Subsidiary Executes SPA to Acquire 51-55% Stake in Swiss Firm Occlutech Holding AG
Alkem Laboratories' subsidiary, Alkem Medtech, has officially signed a Share Purchase Agreement to acquire a controlling stake in Switzerland-based Occlutech Holding AG. The acquisition involves purchasing between 51% and 55% of the total issued equity share capital. This move follows the initial announcement made on February 13, 2026, signaling progress in Alkem's expansion into the medical technology sector. The transaction marks a significant step in Alkem's inorganic growth strategy in international markets.
Key Highlights
Alkem Medtech to acquire a minimum of 51% and a maximum of 55% equity in Occlutech Holding AG
Occlutech Holding AG is a Swiss-incorporated company specializing in medical technology
The Share Purchase Agreement (SPA) was executed on March 06, 2026
The acquisition is being executed through Alkem's wholly-owned subsidiary, Alkem Medtech Private Limited
💼 Action for Investors
Investors should view this as a strategic diversification into the high-growth medical devices segment. Monitor for future disclosures regarding the acquisition valuation and its impact on the company's consolidated debt and margins.
Alkem Laboratories Releases Strategic Roadmap Recording for MedTech Division
Alkem Laboratories has officially released the video recording of its investor meet focused on the strategic way forward for Alkem MedTech. The disclosure, dated February 20, 2026, provides transparency into the company's future plans for its medical technology vertical. This meeting is significant as it outlines how the company intends to diversify beyond traditional pharmaceuticals. Investors can access the full recording via the company's website to evaluate the growth potential of this specific business segment.
Key Highlights
Official recording of the 'Investor meet on Alkem MedTech’s strategic way forward' is now public.
The meeting focused specifically on the future growth drivers and strategy for the MedTech division.
Disclosure made in compliance with SEBI Listing Obligations and Disclosure Requirements (LODR) 2015.
Strategic updates for the MedTech arm indicate a focus on business diversification and long-term value creation.
💼 Action for Investors
Investors should review the recording to understand the capital allocation and revenue expectations for the MedTech business. Monitor the segment's progress as a potential catalyst for valuation rerating beyond the core pharma business.
Alkem MedTech to Acquire 51-55% Stake in Occlutech Holding AG for €180.70 Million
Alkem Laboratories' subsidiary, Alkem MedTech, has executed a binding term sheet to acquire a majority stake (51-55%) in Occlutech Holding AG for an equity value of €180.70 million (approx. ₹19,516 million). Occlutech is a leading global player in the structural heart occluder market, ranking 2nd in Europe and 3rd globally, with 2025 net sales of €50 million. This acquisition provides Alkem with a robust global platform, including 200+ patents and a presence in high-barrier markets like the US, EU, and Japan. The transaction is expected to close by June 2026 and will be funded entirely through internal accruals and existing cash balances.
Key Highlights
Acquisition of 51-55% stake in Occlutech Holding AG at an equity value of €180.70 million (₹19,516 million).
Occlutech reported €50 million in net sales for 2025 with a 14% CAGR from 2021-2025.
Strategic entry into the $680 billion global MedTech market, specifically targeting the high-margin cardiovascular and musculoskeletal segments.
Alkem MedTech aims for a 10% market share in the Indian large joints market within 5 years, targeting 250,000+ implants.
Transaction includes a strong R&D pipeline with US FDA approval for PFO occluders expected by June 2027.
💼 Action for Investors
Investors should view this as a significant strategic pivot towards high-margin medical technology that diversifies Alkem's traditional pharma portfolio. Monitor the successful integration of Occlutech and the progress of US FDA approvals for their pipeline products as key valuation re-rating triggers.
Alkem Labs Q3 FY26 Revenue Up 10.7% to ₹3,737 Cr; Announces Strategic MedTech Acquisition
Alkem Laboratories reported a steady Q3 FY26 with revenue growing 10.7% YoY to INR 37,368 million, driven by a robust 26.6% growth in international markets. The company announced a significant strategic entry into the MedTech space through the acquisition of Occlutech, targeting INR 1,000 crore in revenue from this segment within 3-5 years. While domestic growth was a modest 5.5% due to a high base effect, the company outperformed the Indian Pharmaceutical Market (IPM) in key therapies like anti-infectives and vitamins. EBITDA margins remained healthy at 22.2%, despite an exceptional charge of INR 528 million related to new labour codes.
Key Highlights
Total revenue increased 10.7% YoY to INR 37,368 million, with international sales surging 26.6% to INR 12,157 million.
EBITDA grew 9% YoY to INR 8,280 million with a margin of 22.2%.
Management targets MedTech revenue of INR 1,000 crore with 25% EBITDA margins in the next 4-5 years.
Outperformed IPM in 6 therapies, notably growing 2x the market in Vitamins and 1.4x in Anti-infectives.
Net profit stood at INR 6,360 million, impacted by a INR 528 million exceptional item for Labour Code compliance.
💼 Action for Investors
Investors should monitor the integration of the Occlutech acquisition as it represents a high-margin, technology-led growth lever for the company. The stock remains a strong play on domestic market leadership and expanding international footprint.
Alkem Subsidiary Enzene Receives USFDA Form 483 with 6 Observations for Pune Facility
Alkem Laboratories' subsidiary, Enzene Biosciences, underwent a USFDA Pre-Approval Inspection (PAI) at its Chakan, Pune facility which concluded on February 13, 2026. The inspection resulted in the issuance of a Form 483 with 6 procedural observations. Importantly, the facility received zero observations related to data integrity, which is a critical metric for regulatory compliance. The company is currently preparing a response to address these observations within the stipulated timeline.
Key Highlights
USFDA completed a Pre-Approval Inspection (PAI) at the Chakan, Pune facility on February 13, 2026
The inspection concluded with a Form 483 containing 6 procedural observations
Zero observations were reported regarding data integrity, validating the subsidiary's quality systems
Enzene Biosciences is a subsidiary of Alkem Laboratories Limited
The company has initiated corrective and preventive actions to address the USFDA's findings
💼 Action for Investors
Investors should monitor the company's ability to resolve these 6 procedural observations promptly to secure final approval. The absence of data integrity issues is a positive sign, reducing the likelihood of more severe regulatory escalations like a Warning Letter.
USFDA Issues Form 483 with 6 Observations for Alkem Subsidiary Enzene Biosciences
Alkem Laboratories' subsidiary, Enzene Biosciences, has completed a USFDA Pre-Approval Inspection (PAI) at its manufacturing facility in India. The inspection concluded with the issuance of a Form 483 containing 6 procedural observations. Crucially, the company reported zero observations related to data integrity, which is a positive indicator for the reliability of their quality systems. Enzene is currently preparing a formal response and has initiated corrective and preventive actions to address the findings.
Key Highlights
USFDA completed a Pre-Approval Inspection (PAI) at Enzene Biosciences' Indian facility.
Form 483 issued with 6 procedural observations at the conclusion of the audit.
Zero observations reported regarding data integrity, validating the reliability of regulatory filings.
Company is preparing a response to be submitted within the stipulated timeline.
Corrective and preventive actions (CAPA) have already been initiated by the subsidiary.
💼 Action for Investors
Investors should monitor for the final Establishment Inspection Report (EIR) to ensure these procedural observations do not escalate. The absence of data integrity issues is a significant positive that reduces the risk of severe regulatory sanctions.
Alkem Laboratories to Host Investor Meet for MedTech Strategy on Feb 18, 2026
Alkem Laboratories has scheduled an investor meet for February 18, 2026, specifically to outline the strategic direction of Alkem MedTech. The meeting will involve senior leadership from both the parent company and the MedTech division to discuss future growth plans. This event is significant as it signals a focused push into the medical technology sector, which could diversify the company's revenue streams. Investors should watch for specific details on product development and market positioning during this session.
Key Highlights
Investor meet scheduled for February 18, 2026, at 4:30 PM in Mumbai.
The primary agenda is to outline Alkem MedTech’s 'strategic way forward'.
Senior leadership from both Alkem Laboratories and Alkem MedTech will be present for the briefing.
The division focuses on 'Innovative, Affordable, and Accessible' medical technology solutions.
💼 Action for Investors
Investors should monitor the post-event disclosures for specific capital expenditure plans and revenue guidance for the MedTech division. This vertical could be a key differentiator for Alkem's long-term valuation.
Alkem Laboratories to Outline MedTech Strategic Roadmap on February 18, 2026
Alkem Laboratories has scheduled an investor meet for February 18, 2026, to specifically discuss the strategic direction of its MedTech division. The meeting will feature senior leadership from both the parent company and Alkem MedTech to present the 'strategic way forward.' This event is significant as it indicates a focused effort to scale the medical technology business, which could diversify the company's traditional pharmaceutical revenue base. Investors should monitor the session for details on product pipelines, market entry strategies, and capital expenditure plans for this segment.
Key Highlights
Investor meet scheduled for February 18, 2026, at 4:30 PM IST in Mumbai.
The primary agenda is to outline Alkem MedTech’s strategic roadmap and future growth plans.
Senior leadership from both Alkem Laboratories and Alkem MedTech will be present to interact with institutional investors.
The session aims to highlight the company's focus on innovative, affordable, and accessible medical technology solutions.
💼 Action for Investors
Investors should track the post-meet presentation or transcript to understand the scale of Alkem's MedTech ambitions and its projected contribution to the bottom line. This segment could be a long-term value unlock if the strategy demonstrates a clear path to high-margin growth.
Alkem MedTech to Acquire 55% Stake in Switzerland's Occlutech for INR 1,074 Crore
Alkem Laboratories' subsidiary, Alkem MedTech, has announced a binding offer to acquire a 55% majority stake in Swiss-based Occlutech Holding AG for approximately INR 1,074 crore (EUR 99.4 million). Occlutech is a leading global player in minimally invasive cardiac implants, ranking second in Europe and third globally. The company reported 2025 revenues of EUR 49.4 million with a 15.7% CAGR over the last three years, primarily from European and US markets. This acquisition marks Alkem's strategic entry into the high-barrier cardiovascular devices segment and significantly expands its global medical technology footprint.
Key Highlights
Acquisition of up to 55% stake in Occlutech Holding AG for EUR 99.4 million (approx. INR 1,074 crore)
Occlutech is the 2nd largest company in Europe and 3rd globally in minimally invasive cardiac implants
Target company recorded revenue of EUR 49.4 million in 2025 with a 15.7% CAGR over three years
Provides immediate access to high-value regulated markets including the US, Japan, and Germany
Transaction is expected to be completed by June 2026 subject to regulatory approvals
💼 Action for Investors
Investors should view this as a significant long-term growth driver that diversifies Alkem's revenue stream into high-margin medical technology. Monitor the progress of regulatory approvals and the subsequent integration of Occlutech's R&D capabilities.
Alkem Labs Approves Amendment for Saudi Arabia JV; Retains 51% Controlling Stake
Alkem Laboratories has updated its Joint Venture (JV) plans in Saudi Arabia by amending the Shareholders' Agreement. The company will maintain a 51% majority stake in the new subsidiary, while the 49% partner stake will now be held by Vitals Biotech Company instead of an individual partner. This administrative change facilitates the company's strategic entry into the Middle Eastern pharmaceutical market. The board's approval on February 13, 2026, signals continued progress on this international expansion initiative.
Key Highlights
Alkem Laboratories to hold a 51% majority stake in the Saudi Arabian Joint Venture.
JV partner stake of 49% transferred from Mr. Abdulaziz Alsheikh to his wholly-owned firm, Vitals Biotech Company.
Board of Directors approved the amendment to the Shareholders' Agreement on February 13, 2026.
The JV follows an initial agreement executed on August 12, 2025, for expansion into the Kingdom of Saudi Arabia.
💼 Action for Investors
Investors should monitor the progress of this JV as it represents a key geographical diversification into the GCC region. No immediate action is required as this is an administrative update to a previously announced expansion plan.
Alkem Subsidiary Enzene Biosciences to Raise ₹26.16 Crore via Series B CCPS
Alkem Laboratories' subsidiary, Enzene Biosciences, has entered into an amendment agreement to raise approximately ₹26.16 crore through a private placement. The funding involves the issuance of 5,58,302 Series B Compulsorily Convertible Preference Shares (CCPS) and 10 equity shares to F-Prime Capital and ERVI Healthcare. Post-transaction, Alkem will maintain a majority stake of 88.99% in Enzene on a fully diluted basis. This capital infusion by specialized healthcare investors validates the growth potential of Alkem's biotech arm.
Key Highlights
Enzene Biosciences to receive an aggregate infusion of ₹26,16,25,003 from F-Prime and ERVI Healthcare
Securities issued at ₹468.60 per share, including a significant premium of ₹458.60 per share
Alkem Laboratories' shareholding in Enzene will be 88.99% post-allotment on a fully diluted basis
New investors F-Prime and ERVI Healthcare will hold 1.87% and 0.71% respectively
The agreement amends the existing Shareholders' Agreement to include ERVI Healthcare as a party
💼 Action for Investors
Investors should monitor the growth of Enzene Biosciences as it attracts external capital at a premium, which could lead to future value unlocking for Alkem. The continued majority stake ensures Alkem remains the primary beneficiary of the subsidiary's potential success in the biologics space.
Alkem Laboratories to Merge Wholly-Owned Subsidiary Adroit Biomed with Itself
The Board of Alkem Laboratories has approved the amalgamation of its wholly-owned subsidiary, Adroit Biomed Limited (ABL), into the parent company. ABL, which operates in the pharmaceutical, cosmetic, and nutraceutical trading space, reported a revenue of INR 596.8 million for FY25. As ABL is a 100% subsidiary, no new shares will be issued, and the shareholding pattern of Alkem remains unchanged. The merger is intended to streamline the corporate structure, reduce administrative overheads, and consolidate intellectual property assets.
Key Highlights
Adroit Biomed Limited (ABL) to merge into Alkem Laboratories via a scheme of arrangement.
ABL reported FY25 revenue of INR 596.8 million and a net worth of INR 75.7 million.
No cash consideration or share issuance involved as ABL is a 100% subsidiary of Alkem.
The merger aims to integrate business operations and achieve significant reduction in administrative and managerial overheads.
The scheme is subject to approval from the NCLT Mumbai bench and other regulatory authorities.
💼 Action for Investors
This is an internal restructuring aimed at operational efficiency and does not change the fundamental value or shareholding of the company. Investors should treat this as a routine corporate simplification move.
Alkem Laboratories Declares ₹43 Interim Dividend; Q3 Net Profit Rises to ₹6,360 Million
Alkem Laboratories has declared a substantial interim dividend of ₹43 per share for FY 2025-26, with the record date set for February 20, 2026. The company reported a 10.7% year-on-year increase in consolidated revenue from operations, reaching ₹37,368.2 million for Q3 FY26. Despite an exceptional loss of ₹527.9 million during the quarter, net profit attributable to owners grew to ₹6,360.2 million from ₹6,258.2 million in the previous year. For the nine-month period, the company showed strong performance with net profit rising to ₹20,653.4 million compared to ₹18,596.2 million in the prior year.
Key Highlights
Declared an interim dividend of ₹43 per equity share (2150% of face value).
Consolidated Revenue from Operations grew 10.7% YoY to ₹37,368.2 million in Q3 FY26.
Net Profit attributable to owners increased to ₹6,360.2 million for the quarter.
Nine-month (9M FY26) Net Profit rose to ₹20,653.4 million from ₹18,596.2 million YoY.
Dividend record date is February 20, 2026, with payment starting March 6, 2026.
💼 Action for Investors
Investors should ensure they hold shares by the record date of February 20 to qualify for the ₹43 dividend. The steady revenue growth and healthy dividend payout reflect strong cash flows and operational stability.
Alkem Labs Declares Rs 43 Interim Dividend; Q3 Net Profit Rises to Rs 6,360 Million
Alkem Laboratories has declared a substantial interim dividend of Rs. 43 per equity share for the financial year 2025-2026, with the record date fixed as February 20, 2026. The company reported a consolidated revenue of Rs. 37,368.2 million for Q3 FY26, up from Rs. 33,742.8 million in the same quarter last year. Net profit attributable to owners for the quarter stood at Rs. 6,360.2 million, reflecting steady growth. Dividend payments are scheduled to commence from March 6, 2026.
Key Highlights
Declared an interim dividend of Rs. 43 per equity share (2150% of face value).
Consolidated Q3 FY26 revenue grew to Rs. 37,368.2 million from Rs. 33,742.8 million YoY.
Net profit for the quarter attributable to owners reached Rs. 6,360.2 million.
Record date for dividend eligibility is February 20, 2026, with payment starting March 6, 2026.
Nine-month (9M FY26) revenue increased to Rs. 111,089.5 million compared to Rs. 98,207.7 million YoY.
💼 Action for Investors
Investors interested in the dividend payout should ensure they hold the stock before the record date of February 20, 2026. The consistent revenue growth and strong dividend yield make it a positive signal for long-term shareholders.
Alkem Labs Q3 Profit Up 1.9% YoY to ₹653 Cr; Declares ₹43 Interim Dividend
Alkem Laboratories reported a 10.7% YoY increase in consolidated revenue to ₹37,368.2 million for the quarter ended December 31, 2025. Net profit grew modestly by 1.9% YoY to ₹6,530.3 million, impacted by an exceptional loss of ₹527.9 million during the quarter. A significant highlight for shareholders is the declaration of a substantial interim dividend of ₹43 per share. While YoY performance remains positive, the company experienced a sequential decline in both revenue and profit compared to Q2 FY26.
Key Highlights
Consolidated Revenue from Operations rose 10.7% YoY to ₹37,368.2 million in Q3 FY26.
Net Profit after tax stood at ₹6,530.3 million, a slight increase from ₹6,407.9 million in Q3 FY25.
Declared an interim dividend of ₹43 per equity share (2150% of face value) with a record date of Feb 20, 2026.
Nine-month FY26 revenue reached ₹111,089.5 million, representing a 13.1% growth over the previous year.
Exceptional items of ₹527.9 million were recorded in the current quarter, impacting the bottom line.
💼 Action for Investors
The modest profit growth and sequential decline suggest margin pressure, but the high interim dividend provides immediate value to shareholders. Investors should monitor the impact of exceptional items and the company's growth trajectory in its core pharmaceutical segments.
Alkem Labs Declares ₹43 Interim Dividend; Q3 Revenue Grows 10.7% YoY
Alkem Laboratories has declared a substantial interim dividend of ₹43 per equity share for FY 2025-26, with the record date set for February 20, 2026. The company reported a consolidated revenue of ₹37,368.2 million for Q3 FY26, marking a 10.7% growth compared to the same quarter last year. Net profit attributable to owners rose slightly to ₹6,360.2 million from ₹6,258.2 million YoY, despite being weighed down by an exceptional loss of ₹527.9 million. For the nine-month period ended December 2025, the company's profit reached ₹20,653.4 million, showing a healthy 11% growth over the previous year.
Key Highlights
Declared an interim dividend of ₹43 per equity share on a face value of ₹2.
Q3 FY26 Revenue from Operations increased 10.7% YoY to ₹37,368.2 million.
Nine-month (9M FY26) Revenue reached ₹111,089.5 million compared to ₹98,207.7 million in 9M FY25.
Net Profit for the quarter stood at ₹6,360.2 million after accounting for an exceptional loss of ₹527.9 million.
The record date for dividend eligibility is February 20, 2026, with payment starting March 6, 2026.
💼 Action for Investors
Investors should ensure they hold shares by the February 20 record date to qualify for the ₹43 dividend. The steady revenue growth and strong 9-month performance indicate solid fundamentals, making it a positive hold for long-term investors.
Alkem Labs Completes Trade Generics Business Transfer for Total Consideration of Rs 532.5 Cr
Alkem Laboratories has finalized the transfer of its trade generics business to its wholly-owned subsidiary, Alkem Wellness Limited. The transaction was conducted as a slump sale on a going concern basis, effective from October 1, 2025. The company received the final balance payment of Rs 32.5 crores on December 30, 2025, bringing the total aggregate sale consideration to Rs 532.5 crores. This internal restructuring is now complete following the terms of the Business Transfer Agreement signed in September 2025.
Key Highlights
Final balance consideration of Rs 32.5 crores received on December 30, 2025
Total aggregate sale consideration for the trade generics business reached Rs 532.5 crores
Business transferred to Alkem Wellness Limited, a 100% wholly-owned subsidiary
Transaction executed as a slump sale on a going concern basis effective October 1, 2025
💼 Action for Investors
As this is an internal transfer to a 100% subsidiary, there is no impact on consolidated financials; investors should focus on whether this restructuring improves operational efficiency in the generics segment.
Alkem Labs Invests Rs 300 Crore in Subsidiary Enzene Biosciences via Rights Issue
Alkem Laboratories has infused approximately Rs 300 crore into its subsidiary, Enzene Biosciences, by subscribing to a rights issue. The company acquired 64.02 lakh equity shares at a price of Rs 468.60 per share, increasing its total stake in the subsidiary to 99.61%. The capital is intended to fund Enzene's capital expenditure and working capital requirements for its biosimilars and biologics business. Enzene has demonstrated strong growth, with its turnover rising from Rs 144 crore in FY23 to Rs 363.62 crore in FY25.
Key Highlights
Total investment of Rs 299.99 crore in Enzene Biosciences Limited.
Acquisition of 64,02,018 equity shares at an issue price of Rs 468.60 per share.
Enzene's revenue grew significantly from Rs 144 crore in FY23 to Rs 363.62 crore in FY25.
Post-allotment, Alkem Laboratories holds a 99.61% stake in the subsidiary.
Funds will be utilized for capex and working capital in the high-growth biosimilars and CDMO segment.
💼 Action for Investors
Investors should monitor the scaling of Enzene as it represents Alkem's foray into the high-potential biologics and CDMO space. The consistent revenue growth in the subsidiary is a positive sign for long-term value creation.